5:13 PM
 | 
May 29, 2013
 |  BC Extra  |  Clinical News

First-line Arzerra meets in Phase III CLL trial

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and partner Genmab A/S (CSE:GEN) said first-line treatment with IV Arzerra ofatumumab plus chlorambucil chemotherapy met the primary endpoint in the Phase III COMPLEMENT-1 trial to treat chronic...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >